Boston Scientific: Proactive Guidance Reset and Resilient Growth Support Buy Rating Despite Lowered Target

Analyst Josh Jennings of TD Cowen maintained a Buy rating on Boston Scientific, reducing the price target to $80.00.

Josh Jennings has given his Buy rating due to a combination of factors, starting with Boston Scientific’s ability to slightly surpass Wall Street expectations in the first quarter on both revenue and earnings. He views the company’s 9.4% organic growth, achieved at the high end of management’s guidance, as evidence of resilient underlying demand across key franchises despite pockets of softness.

Jennings also interprets the lowered full‑year and Q2 guidance, particularly the more conservative assumptions for Watchman and electrophysiology, as a proactive reset that relieves pressure from previously aggressive forecasts. By addressing these concerns head‑on while maintaining strong growth in cardiovascular and several MedSurg segments, he believes the risk‑reward profile is attractive at current levels, supporting his Buy rating even with a reduced $80 price target.

In another report released today, Jefferies also reiterated a Buy rating on the stock with a $100.00 price target.